Q3 2019 (pre-Covid19) shows the future in Nova Leap Health2019
Q3 revenues of $4,424,350
Q3 quarterly EBITDA of $324,676 The reason for the weakened EBITDA is Covid-19 related to Omicron, which hit hard in December. Some administrative expense on the most recent acquisitions and a write-down of one (out of 20) failed acquisitions. Since strengthening the managemen/board and perhaps above all the investment they have made in regional management positions has presumably increased the cost, but will be profitable in the future.
I expect only positive numbers on the last line from now on, although omicron may have had an impact during the beginning in January.
We runs a small family office with Nova Leap Health as by far the largest position now.